24-month Phase I follow-up data show positive outcomes are maintained High levels of investigator and patient satisfaction, excellent safety profileOngoing registrational…
October 09, 2025 02:00 ET | Source: Ariceum Therapeutics Oral presentation by Dr Zan highlighted novel Phase 1/2 SANTANA-225 study…
The National Comprehensive Cancer Network expands interactive library of evidence-based, expert consensus-driven cancer care guidance to now cover treatment for…
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase…
Innovative Campaign Focuses on Early Detection and Empowering Education Throughout October CASTRES, France, Sept. 29, 2025 /PRNewswire/ -- Pierre Fabre Laboratories…
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer…
September 26, 2025 New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with…
Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, Delivering Full Strength of Everolimus via Intravenous Injection AUSTRALIA, Sydney,…
BEDFORD, Mass. and CHICAGO and TOKYO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (NASDAQ: LNTH) and GE HealthCare…
BOSTON, Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion…